A*STAR and Public Research Institutes

<h1>A*STAR and Public Research Institutes</h1> <p>The <strong>Agency for Science, Technology and Research</strong> (<strong>A*STAR</strong>) is Singapore's lead public-sector research and development agency. It is a statutory board under the Ministry of Trade and Industry (<strong>MTI</strong>) and operates research institutes spanning biomedical sciences and physical sciences and engineering, with research entities primarily located at Biopolis and Fusionopolis (<a href="https://www.mti.gov.sg/who-we-are/organisation-structure/statutory-boards-and-department/">MTI, accessed Aug 2026</a>; <a href="https://www.a-star.edu.sg/about">A*STAR About, accessed Aug 2026</a>). A<em>STAR describes itself as a science and technology organisation that bridges academia and industry, collaborates with public and private partners, and nurtures scientific talent for research institutes, the wider research community, and industry (<a href="https://www.a-star.edu.sg/about">A*STAR About, accessed Aug 2026</a>). This article explains A</em>STAR's institutional role, institute structure, and how that differs from national Research, Innovation and Enterprise (<strong>RIE</strong>) policy funding led by the National Research Foundation (<strong>NRF</strong>). Industry-facing biomedical manufacturing context sits in <a href="/en/knowledge/article/sgkb.business-industry.biomedical-and-pharma">biomedical and pharma</a>; university teaching and admissions sit in <a href="/en/knowledge/article/sgkb.education.universities">universities</a>.</p> <h2>Statutory status and mission</h2> <p>A<em>STAR is a statutory board under the Ministry of Trade and Industry (MTI), which lists it among the ministry's statutory boards whose work includes driving research and innovation (<a href="https://www.mti.gov.sg/who-we-are/organisation-structure/statutory-boards-and-department/">MTI, accessed Aug 2026</a>; see also <a href="/en/knowledge/article/sgkb.government-politics.statutory-boards">statutory boards</a>). A</em>STAR describes its role as a public-sector science and technology organisation that bridges academia and industry, develops talent, and pursues research with economic and societal outcomes (<a href="https://www.a-star.edu.sg/about">A*STAR About, accessed Aug 2026</a>).</p> <p>A*STAR's published mission is to advance science and develop innovative technology to further economic growth and improve lives, with research aimed at growth and jobs as well as societal outcomes in healthcare, urban living, and sustainability (<a href="https://www.a-star.edu.sg/about">A*STAR About, accessed Aug 2026</a>). The agency states that it works with other public-sector agencies to develop industry sectors by integrating capabilities for multinational and globally competitive companies, partnering local enterprises, and nurturing R&amp;D-driven start-ups (<a href="https://www.a-star.edu.sg/about">A*STAR About, accessed Aug 2026</a>). Those mission statements describe organisational purpose; they are not a substitute for dated national RIE budget envelopes published under NRF/RIEC processes.</p> <h2>Biomedical and science-engineering institute structure</h2> <p>A*STAR organises research through research institutes, national centres, and programmes under key divisions that include the <strong>Biomedical Research Council</strong> (<strong>BMRC</strong>), the <strong>Science and Engineering Research Council</strong> (<strong>SERC</strong>), and <strong>Innovation and Enterprise</strong> (<strong>I&amp;E</strong>) (<a href="https://www.a-star.edu.sg/about/corporate-profile/organisation-structure">A*STAR organisation structure, accessed Aug 2026</a>). BMRC advances biosciences and bio-innovation for health outcomes and Singapore's biomedical economy, is located at Biopolis, and oversees core capabilities such as bioprocessing, genomics and proteomics, molecular and cell biology, bioengineering and nanotechnology, and computational biology, while also supporting biomedical research in universities and hospitals (<a href="https://www.a-star.edu.sg/about/corporate-profile/organisation-structure">A*STAR organisation structure, accessed Aug 2026</a>). SERC promotes public-sector research in the physical sciences and engineering — including communications, materials, chemicals, computational sciences, microelectronics, advanced manufacturing, and metrology — and engages industry partners to move technologies toward commercialisation (<a href="https://www.a-star.edu.sg/about/corporate-profile/organisation-structure">A*STAR organisation structure, accessed Aug 2026</a>). I&amp;E translates research into impact through industry partnerships, licensing, venture building, and start-up creation (<a href="https://www.a-star.edu.sg/about/corporate-profile/organisation-structure">A*STAR organisation structure, accessed Aug 2026</a>).</p> <p>As listed on A<em>STAR's public research-entities directory when accessed in August 2026, biomedical research institutes include the Bioinformatics Institute (BII), Bioprocessing Technology Institute (BTI), Genome Institute of Singapore (GIS), Infectious Diseases Labs (IDL), Institute for Human Development and Potential (IHDP), Institute of Molecular and Cell Biology (IMCB), Singapore Immunology Network (SIgN), Singapore Institute of Food and Biotechnology Innovation (SIFBI), and Skin Research Labs (SRL) (<a href="https://www.a-star.edu.sg/">A*STAR home, accessed Aug 2026</a>). Science and engineering research institutes listed at the same time include the Advanced Remanufacturing and Technology Centre (ARTC), Institute of Advanced Intelligence and Computing (IAIC), Institute of Microelectronics (IME), Institute of Materials Research and Engineering (IMRE), Institute of Sustainability for Chemicals, Energy and Environment (ISCE²), National Metrology Centre (NMC), and Singapore Institute of Manufacturing Technology (SIMTech) (<a href="https://www.a-star.edu.sg/">A*STAR home, accessed Aug 2026</a>). Institute names and groupings change over time; treat the live A</em>STAR directory as authoritative for the current inventory, and use <a href="/en/knowledge/dataset/sgkb.data.astar-research-entities">astar research entities</a> for a compact identity table tied to that access date.</p> <h3>Institute of Advanced Intelligence and Computing</h3> <p>On 1 July 2026, A<em>STAR announced the formation of the **A</em>STAR Institute of Advanced Intelligence and Computing** (<strong>IAIC</strong>) through the integration of the Institute for Infocomm Research (<strong>I²R</strong>) and the Institute of High Performance Computing (<strong>IHPC</strong>) (<a href="https://www.sgpc.gov.sg/detail?HomePage=home&amp;page=%2Fdetail&amp;url=%2Fmedia_releases%2Fastar%2Fpress_release%2FP-20260701-1">A*STAR statement, 1 July 2026</a>). The new institute brings together capabilities in artificial intelligence, data and digital technologies, modelling and simulation, quantum computing, and high-performance computing. A*STAR described IAIC as supporting AI and digital solutions across research, industry, and the public sector; this is an institutional formation statement, not evidence that every named capability is a separate institute or that all AI work in Singapore sits within IAIC.</p> <p>IAIC is therefore a current A<em>STAR institute identity within the science-and-engineering portfolio, while this article remains the right place to explain A</em>STAR's statutory status, BMRC/SERC structure, and relationship to NRF. The 1 July announcement says IAIC was formed by integrating I²R and IHPC; it does not establish a new national AI regulator, a separate university, or a replacement for AI Singapore.</p> <h2>Universities, hospitals, and industry</h2> <p>A<em>STAR positions its institutes inside a wider public research system rather than as a closed laboratory network. BMRC states that it supports biomedical research in the wider scientific community such as public universities and hospitals, promotes translational and cross-disciplinary work, and crafts partnership programmes intended to attract private biomedical R&amp;D investment into Singapore (<a href="https://www.a-star.edu.sg/about/corporate-profile/organisation-structure">A*STAR organisation structure, accessed Aug 2026</a>). SERC similarly plans multidisciplinary collaborations across industries, institutes, and sectors, and cultivates industry partners through funding schemes and attachment programmes so technologies can move from conception toward commercialisation (<a href="https://www.a-star.edu.sg/about/corporate-profile/organisation-structure">A*STAR organisation structure, accessed Aug 2026</a>). A</em>STAR's about page frames the agency as bridging academia and industry and as a catalyst and convenor of research initiatives among partners in Singapore and beyond (<a href="https://www.a-star.edu.sg/about">A*STAR About, accessed Aug 2026</a>).</p> <p>In practice, that means A<em>STAR institutes are public research performers that collaborate with autonomous universities, clinical partners, multinational corporations, local enterprises, and start-ups, while I&amp;E handles licensing and venture pathways (<a href="https://www.a-star.edu.sg/about">A*STAR About, accessed Aug 2026</a>; <a href="https://www.a-star.edu.sg/about/corporate-profile/organisation-structure">A*STAR organisation structure, accessed Aug 2026</a>). University degree programmes, faculty appointments, and admissions remain under the higher-education system documented in <a href="/en/knowledge/article/sgkb.education.universities">universities</a>; A</em>STAR's role is research performance, talent pipelines into research and industry, and translation — not substituting for university governance. Biomedical manufacturing parks, plant investment, and therapeutic-product licensing are covered in <a href="/en/knowledge/article/sgkb.business-industry.biomedical-and-pharma">biomedical and pharma</a> and should not be collapsed into A*STAR institute identity alone.</p> <h2>Critical perspectives: NRF policy funding versus A*STAR performance</h2> <p>The <strong>National Research Foundation</strong> is a department within the Prime Minister's Office, established on 1 January 2006. NRF sets national direction for research and development by developing policies, plans, and strategies for research, innovation, and enterprise; it also funds strategic initiatives and develops R&amp;D capabilities by nurturing research talent (<a href="https://www.nrf.gov.sg/about/about-nrf-singapore/nrf-singapore/">NRF, accessed Aug 2026</a>). Singapore's multi-year <strong>Research, Innovation and Enterprise</strong> plans are the high-level funding and priority framework for that ecosystem. At a 5 December 2025 press conference launching <strong>RIE2030</strong>, the Government announced investment of S$37 billion over the next five years from April 2026 — described as about one per cent of GDP — continuing the sequence of five-year RIE and earlier science and technology plans (<a href="https://www.pmo.gov.sg/newsroom/sm-lee-hsien-loong-at-the-press-conference-on-the-launch-of-research-innovation-enterprise-2030-plan/">PMO, 5 Dec 2025, accessed Aug 2026</a>).</p> <p>A<em>STAR is a major public research performer and translation agency inside that ecosystem, not the national RIE policy owner. NRF sets direction and funds strategic initiatives; A</em>STAR runs institutes, partners with universities and firms, and commercialises outputs under MTI oversight and its own statute (<a href="https://www.nrf.gov.sg/about/about-nrf-singapore/nrf-singapore/">NRF, accessed Aug 2026</a>; <a href="https://www.mti.gov.sg/who-we-are/organisation-structure/statutory-boards-and-department/">MTI, accessed Aug 2026</a>; <a href="https://www.a-star.edu.sg/about">A*STAR About, accessed Aug 2026</a>). Do not treat an A<em>STAR institute budget, a university grant, or a corporate laboratory announcement as the whole RIE envelope, and do not treat NRF as the operator of Biopolis or Fusionopolis institutes. For dated national plan figures, cite the RIE announcement itself; for which institute exists under BMRC or SERC, cite A</em>STAR's current directory rather than undated secondary summaries.</p>

简介

新加坡科技研究局与公共研究机构

新加坡科技研究局(A*STAR)是新加坡主要的公共部门研究与开发机构。它是贸工部(MTI)下属的法定机构,运营涵盖生物医学、物理科学与工程的研究机构,研究实体主要位于纬壹科技城和纬壹科技城二期(MTI,访问于 2026 年八月; A*STAR 简介,访问于 2026 年八月)。ASTAR 将自身描述为连接学术界与产业界的科学技术机构,与公共和私人合作伙伴协作,并为研究机构、更广泛的研究社群及产业界培养科学人才(A*STAR 简介,访问于 2026 年八月)。本文说明 ASTAR 的机构角色、研究机构架构,以及这与由国家研究基金会(NRF)牵头的国家研究、创新与企业(RIE)政策资助有何不同。面向产业的生物医学制造背景见生物医学与制药;大学教学与招生见大学。

法定地位与使命

贸工部(MTI)将 ASTAR 列为其法定机构之一,这些机构的工作包括推动研究与创新(MTI,访问于 2026 年八月; 另见法定机构)。ASTAR 将自身角色描述为连接学术界与产业界、培养人才并开展能够带来经济和社会成果研究的公共部门科学技术机构(A*STAR 简介,访问于 2026 年八月)。

A*STAR 公布的使命是推进科学并开发创新技术,以促进经济增长和改善生活;研究旨在推动增长和就业,并在医疗保健、城市生活和可持续发展方面取得社会成果(A*STAR 简介,访问于 2026 年八月)。该机构表示,会与其他公共部门机构合作发展产业领域,为跨国及具有全球竞争力的公司整合能力,与本地企业合作,并培育由研发驱动的初创企业(A*STAR 简介,访问于 2026 年八月)。这些使命陈述说明的是机构宗旨,不能替代通过 NRF/RIEC 流程公布的、注明日期的国家 RIE 预算总额。

生物医学与科学工程研究机构架构

A*STAR 通过研究机构、国家中心和项目开展研究,所属关键部门包括生物医学研究理事会(BMRC)、科学与工程研究理事会(SERC)以及创新与企业(I&E)(A*STAR 组织架构,访问于 2026 年八月)。BMRC 推动生物科学与生物创新,以改善健康成果并发展新加坡生物医学经济;其位于纬壹科技城,负责生物加工、基因组学与蛋白质组学、分子与细胞生物学、生物工程与纳米技术、计算生物学等核心能力,同时支持大学和医院的生物医学研究(A*STAR 组织架构,访问于 2026 年八月)。SERC 推动公共部门在物理科学与工程领域的研究,包括通信、材料、化学、计算科学、微电子、先进制造和计量,并与产业伙伴合作,推动技术走向商业化(A*STAR 组织架构,访问于 2026 年八月)。I&E 通过产业合作、许可、创业项目建设和创建初创企业,将研究转化为影响力(A*STAR 组织架构,访问于 2026 年八月)。

据访问于 2026 年八月时 ASTAR 的公共研究实体目录,生物医学研究机构包括生物信息学研究院(BII)、生物工艺技术研究院(BTI)、新加坡基因组研究院(GIS)、传染病实验室(IDL)、人类发展与潜能研究院(IHDP)、分子与细胞生物学研究院(IMCB)、新加坡免疫学网络(SIgN)、新加坡食品与生物技术创新研究院(SIFBI)以及皮肤研究实验室(SRL)(A*STAR 首页,访问于 2026 年八月)。同期列出的科学与工程研究机构包括先进再制造与技术中心(ARTC)、先进智能与计算研究院(IAIC)、微电子研究院(IME)、材料研究与工程研究院(IMRE)、化学品、能源与环境可持续发展研究院(ISCE²)、国家计量中心(NMC)以及新加坡制造技术研究院(SIMTech)(A*STAR 首页,访问于 2026 年八月)。研究机构名称和分组会随时间变化;当前清单应以 ASTAR 实时目录为准,简明身份表可参见 A*STAR 研究实体,该表对应上述访问日期。

先进智能与计算研究院

2026 年七月 1 日,ASTAR 宣布成立**ASTAR 先进智能与计算研究院**(IAIC),由资讯通信研究院(I²R)和高性能计算研究院(IHPC)整合而成(A*STAR 声明,2026 年七月 1 日)。新研究院汇集人工智能、数据与数字技术、建模与仿真、量子计算及高性能计算方面的能力。A*STAR 表示 IAIC 将为研究、产业界和公共部门提供人工智能及数字解决方案;这是关于机构成立的声明,并不表示每项提及的能力都是独立研究院,也不表示新加坡所有人工智能工作都归 IAIC 管辖。

因此,IAIC 是 ASTAR 科学与工程领域中当前的研究院实体;本文仍适合说明 ASTAR 的法定地位、BMRC/SERC 架构及其与 NRF 的关系。七月 1 日的公告称 IAIC 由整合 I²R 和 IHPC 而成立;公告并未表明新设了国家人工智能监管机构、独立大学,或取代了 AI Singapore。

大学、医院与产业界

ASTAR 将其研究机构定位于更广泛的公共研究体系中,而不是封闭的实验室网络。BMRC 表示,它支持包括公立大学和医院在内的更广泛科学社群开展生物医学研究,推动转化研究与跨学科研究,并制定合作计划,以吸引私人对新加坡生物医学研发的投资(A*STAR 组织架构,访问于 2026 年八月)。SERC 同样规划跨产业、研究机构和领域的多学科合作,并通过资助计划和派驻项目培育产业伙伴,使技术从构想走向商业化(A*STAR 组织架构,访问于 2026 年八月)。ASTAR 的简介页面将该机构描述为连接学术界与产业界的桥梁,也是新加坡及其他地区合作伙伴研究计划的催化者和召集者(A*STAR 简介,访问于 2026 年八月)。

实际上,ASTAR 研究机构是公共研究执行者,与自治大学、临床合作伙伴、跨国公司、本地企业和初创企业合作,而 I&E 负责许可和创业路径(A*STAR 简介,访问于 2026 年八月; A*STAR 组织架构,访问于 2026 年八月)。大学学位课程、教职任命和招生仍归高等教育体系管理,相关说明见大学;ASTAR 的职责是开展研究、为研究和产业界培养人才,以及推动成果转化,而非取代大学治理。生物医学制造园区、工厂投资和治疗产品许可见生物医学与制药,不应仅归并为 A*STAR 研究机构身份。

批判性视角:NRF 政策资助与 A*STAR 研究执行

国家研究基金会是总理公署内的一个部门,成立于 2006 年一月 1 日。NRF 通过制定研究、创新与企业领域的政策、计划和战略,确立国家研发方向;它也资助战略项目,并通过培养研究人才来发展研发能力(NRF,访问于 2026 年八月)。新加坡多年期的研究、创新与企业计划是该生态系统的高层资助与优先事项框架。政府在 2025 年十二月 5 日举行的新闻发布会上推出 RIE2030,宣布从 2026 年四月起的未来五年投资 37 亿新元——约占国内生产总值的百分之一——延续此前五年期 RIE 计划及更早的科学技术计划序列(总理公署,2025 年十二月 5 日,访问于 2026 年八月)。

ASTAR 是该生态系统中的主要公共研究执行机构和成果转化机构,而非国家 RIE 政策的主管部门。NRF 负责制定方向并资助战略项目;ASTAR 在 MTI 监督及自身法定授权下运营研究机构,与大学和企业合作,并推动成果商业化(NRF,访问于 2026 年八月; MTI,访问于 2026 年八月; A*STAR 简介,访问于 2026 年八月)。不要将 ASTAR 研究机构预算、大学拨款或企业实验室公告视为整个 RIE 预算总额,也不要将 NRF 视为纬壹科技城或纬壹科技城二期研究机构的运营方。引用注明日期的国家计划数据时,应引用 RIE 公告本身;说明 BMRC 或 SERC 下设有哪些研究机构时,应引用 ASTAR 当前目录,而非未注明日期的二手摘要。